Related Experiment Videos
MPA at high doses in advanced breast cancer: a statistical evaluation
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy
|June 1, 1986
Summary
Medroxyprogesterone acetate (MPA) therapy showed a pain-control effect in advanced cancer patients with higher plasma levels. Response correlation was observed in mammary cancer patients with visceral metastases.
Area of Science:
- Pharmacology
- Oncology
- Clinical Pharmacy
Background:
- Medroxyprogesterone acetate (MPA) is used in cancer therapy.
- Understanding its efficacy and patient response is crucial.
Purpose of the Study:
- To analyze clinical and pharmacokinetic data of MPA therapy in cancer patients.
- To identify predictors of response and non-response to MPA.
Main Methods:
- Retrospective analysis of clinical and pharmacokinetic data from 380 cancer patients.
- Utilized discriminant analysis to evaluate prognostic factors for breast cancer response.
Main Results:
- A correlation between bioavailability and objective response was found in mammary cancer patients with visceral metastases.
- Pain control was observed in advanced cancer patients when MPA plasma levels exceeded 150-200 ng/ml.
- Receptorial status, metastasis site, alkaline phosphatase, and free interval predicted response; prolactin and prior treatments predicted non-response.
Conclusions:
- MPA shows specific efficacy in certain cancer patient subgroups.
- Prognostic factors can predict response, but combining them does not improve predictive efficacy.